Promega and Roche wait for verdict in their patent dispute over the taq enzyme
This article was originally published in Clinica
Executive Summary
Promega's patent battle with Roche over the taq enzyme used in the polymerase chain reaction (PCR) process will be decided in the autumn. The trial ended last week with Madison, Wisconsin-based Promega confident that its argument had persuaded the federal district judge in a San Francisco court that Roche's US patent was obtained by fraud.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.